<DOC>
	<DOCNO>NCT00153088</DOCNO>
	<brief_summary>The aim study compare preventive effect Telmisartan ( Micardis ) versus placebo control transition overt nephropathy patient diabetic nephropathy manifest microalbuminuria associate type II diabetes , evaluate efficacy safety Telmisart ( Micardis , Gliosartan , Kinzal , Kinzalmono , Predxal , Pritor , Samertan , Telmisartan ) diabetic nephropathy patient .</brief_summary>
	<brief_title>INNOVATION Study - Telmisartan ( Micardis ) Incipient Diabetic Nephropathy</brief_title>
	<detailed_description>A prospective , randomised , double-blind , multicentric comparative study investigate , long-term basis , preventive effect transition overt nephropathy safety Telmisartan ( Micardis ) placebo patient diabetic nephropathy , manifest microalbuminuria associate type II diabetes . Study Hypothesis : The hypothesis Telmisartan ( Micardis ) 40 mg 80 mg versus placebo control patient concurrent type II diabetic mellitus diabetic nephropathy demonstrate microalbuminuria , preventive effect transition incipient overt nephropathy . Comparison ( ) : The primary endpoint define transition incipient overt nephropathy , non-transition curve demonstrate base Kaplan-Meier method . The evaluation criterion point transition overt nephropathy define urinary albumin creatinine ratio consecutive 2 measure point increase 300 mg/g-Creatinine excess 30 % increase compare baseline value . The curve non-transition compare Logrank test . Those BIBR277 group sequentially compare placebo group close test procedure .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<criteria>1 . Outpatients able visit study site throughout runin period 2 . Aged 30 74 year 3 . Type II diabetes mellitus 4 . Patients urinary albumin creatinine ratio within follow range 2 measure point runin period 1 ) firstmorning voided urine , iin range 100 300 mg/g Creatinine 2 ) &lt; 100 mg/g Creatinine either point Visit 2 3 , range 100 300 mg/g Creatinine followup 5 . Serum creatinine level &lt; 1.5 mg/dL male &lt; 1.3 mg/dL female 6 . Normotensive hypertensive patient 7 . Patients take AT1 antagonist ACE inhibitor screen , able stop drug study 8 . Patients able provide write informed consent accordance Good Clinical Practice ( GCP ) relevant law Pharmaceutical Affairs Law 1 . Age onset type 2 diabetes &lt; 30 year 2 . Type I diabetes 3 . Urinary albumin creatinine ratio &gt; 300 mg/g Creatinine 4 . HbA1c 9 % 5 . Seated SBP 180 mmHg DBP 110 mmHg 6 . Findings suggest renal disease diabetic nephropathy ; post renal transplantation , history nondiabetic renal disease , mark haematuria , complication urinary tract infection 7 . Cardiovascular disease : Patients unstable angina , myocardial infarction , CABG , PTCA within 6 month CHF NYHA IIIIV TIA within 6 month Stroke within 6 month AV block ( grade IIIII ) AF Serious arrhythmia Known suspect secondary HT 8 . History angioedema administration ARB/ACEi 9 . Hypersensitivity 10 . History sudden exacerbation renal function due ARB/ACEi 11 . Markedly poor bile secretion 12 . Hepatic dysfunction : SGPT ( ALT ) SGOT ( AST ) 100 IU/L 13 . Serum potassium level &lt; 3.5 mEq/L 5.1 mEq/L 14 . Unable discontinue ARB/ACEi 15 . Require prolonged administration medication affect blood pressure , except diuretic , blocker , CCB 16 . Untreated sodium depletion 17 . Premenopausal females meet one follow : Pregnant possibly pregnant Breastfeeding Hope pregnant study period Even patient confirm meet criterion start study , female patient potential pregnant study undergo pregnancy test . If result turn positive , study medication discontinue . 18 . Malignant tumour disease require oral injection immunosuppressant 19 . Noncompliance 20 . History drug alcohol abuse 21 . Participated clinical study within 3 month 22 . Any condition investigator judge ineligible</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>